Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Gain (Loss)	Accumulated Deficit	Noncontrolling Interest
Beginning Balance at Dec. 31, 2020	$ 743,266	$ 14	$ 1,253,971	$ 893	$ (511,612)
Beginning Balance, Shares at Dec. 31, 2020		137,646,896
Issuance of common stock upon exercise of common stock warrant, Shares		54,162
Issuance of common stock for cash upon exercise of stock options	23,299		23,299
Issuance of common stock for cash upon exercise of stock options, Shares		3,310,804
Vesting of restricted stock units		15,625
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	31,376		31,376
Capital contributions for Digital Biotechnologies, Inc.	429		300			$ 129
Other comprehensive loss	(886)			(886)
Net loss	(145,941)				(145,846)	(95)
Ending Balance at Sep. 30, 2021	651,543	$ 14	1,308,946	7	(657,458)	34
Ending Balance, Shares at Sep. 30, 2021		141,027,487
Beginning Balance at Jun. 30, 2021	693,310	$ 14	1,294,506	216	(601,555)	129
Beginning Balance, Shares at Jun. 30, 2021		140,663,755
Issuance of common stock for cash upon exercise of stock options	2,797		2,797
Issuance of common stock for cash upon exercise of stock options, Shares		360,607
Vesting of restricted stock units		3,125
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	11,643		11,643
Other comprehensive loss	(209)			(209)
Net loss	(55,998)				(55,903)	(95)
Ending Balance at Sep. 30, 2021	651,543	$ 14	1,308,946	7	(657,458)	34
Ending Balance, Shares at Sep. 30, 2021		141,027,487
Beginning Balance at Dec. 31, 2021	604,102	$ 14	1,324,006	(1,137)	(718,891)	110
Beginning Balance, Shares at Dec. 31, 2021		141,393,865
Issuance of common stock for cash upon exercise of stock options	$ 7,562		7,562
Issuance of common stock for cash upon exercise of stock options, Shares	1,361,891	1,361,891
Vesting of restricted stock units		231,371
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	$ 41,183		41,183
Other comprehensive loss	(4,834)			(4,834)
Net loss	(160,199)				(160,063)	(136)
Ending Balance at Sep. 30, 2022	487,814	$ 14	1,372,751	(5,971)	(878,954)	(26)
Ending Balance, Shares at Sep. 30, 2022		142,987,127
Beginning Balance at Jun. 30, 2022	518,316	$ 14	1,357,763	(5,800)	(833,673)	12
Beginning Balance, Shares at Jun. 30, 2022		142,784,868
Issuance of common stock for cash upon exercise of stock options	846		846
Issuance of common stock for cash upon exercise of stock options, Shares		131,802
Vesting of restricted stock units		70,457
Common stock option, restricted stock unit and market-based restricted stock unit share-based compensation	14,142		14,142
Other comprehensive loss	(171)			(171)
Net loss	(45,319)				(45,281)	(38)
Ending Balance at Sep. 30, 2022	$ 487,814	$ 14	$ 1,372,751	$ (5,971)	$ (878,954)	$ (26)
Ending Balance, Shares at Sep. 30, 2022		142,987,127